Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3849891 subcutaneous single-ascending and repeated-dose study in MASLD with PNPLA3 I148M genotype
jRCT2031220200Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 1 trial of LY3849891 in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with one or more treatment-emergent adverse events and adverse events considered related to study drug and Mean change from baseline in liver inflammation and fibrosis measured by MRI. Started Jul 2022; status: completed.
02
Drugs
LY3849891
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031220200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220200.